XERSXeris Biopharma Holdings Inc.
+1.8% today · +15.3% over a year
4/10 A 1–10 summary of how an instrument compares with similar ones (same sector and region) by published rules. It describes today's data; it is not a price forecast. More in the glossary → «Balanced» — higher than 70% of the instruments we score
Quality: among the best of its peers. No dividend.
Xeris Biopharma Holdings Inc. (XERS) belongs to the Health care sector and is listed on Nasdaq; country: United States. Its market value is about €1.7B. Over the past 12 months the price changed by +15.3%, with an annualised volatility of 55% and a largest fall of 47%.
Smart Score
How it is scored →The Smart Score (1–10) describes how this instrument compares with its peers on published, rules-based measures of value, quality, trend, stability and dividend safety. It is not a forecast and not personal advice.
Compared with: Health care companies in USA (n = 337)
Current rating first published: · last recomputed · rating log
Factor scores
Percentiles within the peer group (100 = the best of its peers); dividend safety in points.
Main drivers
- Gross profit growth / assets (5 y)supports the score · better than 91% of peers
- Piotroski F-scoresupports the score · better than 95% of peers
- Return on invested capitalsupports the score · better than 93% of peers
Red flags and notes
- Caution. Share count growing 3–10 % a year over three years. More in the glossary → Share count growing 3–10 % a year over three years.
- Caution. Net debt above 4× EBITDA or interest cover below 2×. More in the glossary → Net debt above 4× EBITDA or interest cover below 2×.
- Caution. Book equity is below zero. More in the glossary → Book equity is below zero.
Price chart
Interactive chart by TradingView: exchange prices are delayed, crypto and currencies are live.
Key metrics
Valuation
- P/S
- 5.8
- EV/EBIT
- 56.6
- Market cap (EUR)
- €1.7B
Profitability and debt
- Return on invested capital
- 28.0%
- Gross margin
- 86.6%
- Net debt / EBITDA
- 3.45
Dividends
- Dividend yield
- 0.00%
- Years of dividend growth
- 0
Returns and risk
- 1 day
- +1.8%
- 1 month
- +8.2%
- 1 year
- +15.3%
- Volatility, 1 yr
- 54.6%
- Max drawdown, 1 yr
- −46.6%
- Beta
- 1.07
Ratios from SEC filings and end-of-day prices; returns are price changes without dividends.
Similar companies
Same sector and region, closest in market value.
| WGSGeneDx Holdings Corp. | 2/10 | 0.0% | −52.9% |
|---|---|---|---|
| TRVITrevi Therapeutics Inc. | 1/10 | 0.0% | 28.4% |
| LMATLeMaitre Vascular Inc. | 7/10 | 1.1% | −6.5% |
| MLYSMineralys Therapeutics Inc. | —/10 | 0.0% | −47.4% |
| XRAYDentsply Sirona | 2/10 | 1.7% | −26.7% |
| ZBIOZenas BioPharma Inc. | 1/10 | 0.0% | −4.7% |
| NTLAIntellia Therapeutics Inc | 1/10 | 0.0% | −4.6% |
| VIRVir Biotechnology | 2/10 | 0.0% | 85.5% |
News and filings
- Xeris Biopharma Holdings, Inc.: 8-K — Other events
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 14 Oct 2026
- Xeris Biopharma Holdings, Inc.: 8-K — Regulation FD disclosure
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 9 Sep 2026
- Xeris Biopharma Holdings, Inc.: 10-Q — Quarterly report for the period ending 30 Jun 2026
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 6 Aug 2026
- Xeris Biopharma Holdings, Inc.: 8-K — Results of operations
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 6 Aug 2026
What the marks mean
- FactA filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.
- Media reportA headline from a named media outlet. We link to it and do not check it.
- RumourUnconfirmed: the headline itself hedges (“reportedly”, “sources say”, “in talks”), names no publisher, or comes from a news aggregator or an automated republisher.
Source: Filings: U.S. SEC EDGAR. The tone is scored automatically from the headline and can be wrong.
Score changes in the last 12 months
Every published rating and change, logged when it was published (EU Market Abuse Regulation).
Show the log: 2 entries
| Date | Event | Balanced | Growth · Income | Warnings | Price at publication |
|---|---|---|---|---|---|
| Rating change | 3 → 4/10 | 4 · — | — | Available with Invest Pro | |
| First rating | 3/10 | 3 · — | Available with Invest Pro |
Ratings are rules-based descriptions, valid until the next scoring run (about 06:20 and 21:50 UTC) and the same for every visitor.
Withdraw from contract here · EU consumers: 14 days to withdraw from a purchase.